Navigation Links
Data Presented For ENMD-2076 In Preclinical Models Of Triple-Negative Breast Cancer
Date:10/21/2013

clinical applications. Taken together, we believe they will shed additional light on more advanced clinical trials and enhance the value of ENMD-2076."  

To view the poster presentation, visit the Company's website at http://www.entremed.com.

About ENMD-2076
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.  ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase.  Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers.  ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers.  ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, multiple myeloma, and is currently completing a Phase 2 trial for ovarian cancer.  EntreMed is currently conducting a Phase 2 study of ENMD-2076 in triple-negative breast cancer, a Phase 2 study in advanced/metastatic soft tissue sarcoma, and expecting to initiate a Phase 2 study in ovarian clear cell carcinoma.  ENMD-2076 has received orphan drug designation from the FDA for the treatment of ovarian cancer, multiple myeloma and acute myeloid leukemia.

About EntreMed
EntreMed is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market.  Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer.  EntreMed is currently conducting a Phase 2 stud
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis to be Presented at AASLD Annual Meeting
2. Pivotal Phase 3 Data from Boehringer Ingelheim Hepatitis C Portfolio to be Presented at 64th Annual AASLD Meeting
3. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
4. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
5. Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting
6. Data From Post-Hoc Analyses Presented at EASD Examine Safety Profile of Linagliptin in Adults with Type 2 Diabetes
7. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials to be Presented at the 2013 San Antonio Breast Cancer Conference
8. LipoScience Announces Data Presented at the 2013 American Diabetes Association Meeting
9. New data about the safety and efficacy of linagliptin in adults with type 2 diabetes who have moderate to severe renal impairment presented at ADA
10. Ibrutinib Monotherapy Clinical Trial Data in Patients with Waldenstroms Macroglobulinemia Presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland
11. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... DUBLIN , Apr. 16, 2015 Research and ... addition of the "Corporate Reputation of Pharma in ... - 1st Edition" report to their offering. ... has compared opinions on the corporate reputation of the ... in mental health with the views of patient organisations ...
(Date:4/17/2015)... , April 17, 2015 Bionomics Limited ... and development of innovative therapeutics for the treatment of ... announced the presentation of data from three of its ... for Cancer Research (AACR) 106 th Annual Meeting ... Philadelphia, PA USA. The ...
(Date:4/16/2015)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... commercialization of products for the treatment of central nervous ... the first quarter of 2015 on Wednesday, May 6, ... Company will host a conference call at 4:30 PM ... management will discuss the first quarter 2015 financial results ...
Breaking Medicine Technology:Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 2Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 3Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 4Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 5Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2
... 2011 Life Technologies Corporation (Nasdaq: ... semiconductor sequencing chip will be available for early access ... and analysis software, providing up to 1Gb of data ... 314 chip introduced two months ago with the ...
... Omnicell, Inc ., (Nasdaq: OMCL ... healthcare facilities, today announced the results of a survey ... to identify trends in requirements for vendor interoperability and ... that the majority of hospitals recognize the critical role ...
Cached Medicine Technology:Life Technologies to Launch Ion 318 Chip in Second Half of 2011 with 1Gb of Data Output 2Life Technologies to Launch Ion 318 Chip in Second Half of 2011 with 1Gb of Data Output 3Life Technologies to Launch Ion 318 Chip in Second Half of 2011 with 1Gb of Data Output 475 Percent of Hospital IT Leaders View Interoperability Between Vendor Systems as Critical to Operational Effectiveness in Healthcare Settings 2
(Date:4/17/2015)... 2015 John Evans, a Gardant affordable ... Patio from 2 p.m. to 3 p.m. on April ... Executive Ct. in Pekin, Illinois, serves older adults of ... help to maintain their independence. , Becky Baker will ... will be served during the luau. , For more ...
(Date:4/17/2015)... Beach, California (PRWEB) April 17, 2015 ... surgeon Dr. Kevin Sadati of the Gallery ... of Orange County’s top beauty experts. The publication ... neck lift, facial stem cell fat grafting, eyelid surgery, ... to facial plastic surgery has resulted in ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 “We have seen ... of the past and present,” said Chaplain Shawn Kafader of ... hadn’t felt like they had anything to contribute have created ... has overseen a new art therapy program that was launched ... a Masters student from School of the Art Institute in ...
(Date:4/17/2015)... CA (PRWEB) April 17, 2015 Consumers ... insurance protection without modifications can now use the Insurance ... general life insurance policy rates that are featured by ... The standard plans that are offered are mixed between ... aged 18 to 79. There are now term, universal ...
(Date:4/17/2015)... As a board-certified orthopedic surgeon, Dr. ... of platelet-rich plasma (PRP) and stem cell ... known for its world-class care of injury-caused and chronic ... lacking in many other physicians offering regenerative medicines. ... for pain management and rehabilitation. Dr. Meier and MOSM ...
Breaking Medicine News(10 mins):Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 2Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 3Health News:Healing At Friendship Village Due To Art Therapy 2Health News:General Life Insurance Policy Rates Added to Quotation System at Insurance Website Online 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3
... More than 250 experts have got together for a conference ... the curtain raiser, of what is going to be a ... Forum was instituted in 2005 by the parliament's corporate body ... channels of communication between politicians, academics and international organizations. ...
... the common cause of amnesia, also prevents victims from thinking ... present. ,Researchers, reporting their study in Tuesday's ... the Wellcome Trust Centre for Neuroimaging, University College London, examined ... that is crucial in learning and memory. ...
... a research they will back all the way through. , ... with the aim of getting the recipient pregnant. // ,The ... difficulties though. ,The wombs would come from dead donors, ... the recipient gives birth so she would not need anti-rejection drugs ...
... Australia health providers is busy counting its losses. ... doctors resort to rorting or over servicing, //by prescribing ... ,The loss in figure s caused by over billing ... body releases its 'Report to the Professions', which looks ...
... be best for your health. A new study found that ... to the bacterium Helicobacter pylori, //and younger siblings from large ... type of stomach cancer. ,These latest findings are ... who were followed over a 28-year period. The researchers found ...
... linked a structural protein called nestin to a particularly ... that could lead to earlier detection and better treatment.// ... Research, researchers from Dartmouth Medical School demonstrate that nestin ... breast tumors, a highly aggressive cancer with similarities to ...
Cached Medicine News:Health News:Amnesia Halts Future Thinking: Study 2Health News:Uterus Transplant- A Future Reality 2Health News:Link Between Family Size and Stomach Cancer Found 2Health News:Link Between Family Size and Stomach Cancer Found 3Health News:Selective Marker Found to Indicate Aggressive Form of Breast Cancer 2Health News:Selective Marker Found to Indicate Aggressive Form of Breast Cancer 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: